AVROBIO, Inc. (AVRO)
| Previous close | 1.2300 |
| Open | 1.2300 |
| Bid | 1.2000 x 100 |
| Ask | 1.2500 x 100 |
| Day's range | 1.1800 - 1.2400 |
| 52-week range | 0.5700 - 1.7000 |
| Volume | |
| Avg. volume | 220,879 |
| Market cap | 54.751M |
| Beta (5Y monthly) | 1.24 |
| PE ratio (TTM) | 4.52 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
AVROBIO and Tectonic Therapeutic Announce Merger
CAMBRIDGE, Mass. & WATERTOWN, Mass., January 30, 2024--AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the "Merger"). Under the terms of the agreement, AVR
- Business Wire
AVROBIO to Explore Strategic Alternatives
CAMBRIDGE, Mass., July 12, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. AVROBIO has made the determination to halt further development of its programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.
- Business Wire
AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million
CAMBRIDGE, Mass., June 12, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the closing of the previously announced agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for cystinosis to Novartis for $87.5 million in cash.
